ClinicalTrials.gg
CompletedNCT03104374SELECT - PsA 2Updated Sep 11, 2025Results posted

A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug

A Phase 3 interventional study of Placebo and Upadacitinib in Psoriatic Arthritis, sponsored by AbbVie. Completed at 165 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-11.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
642
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 34 studies in Arthritis, Psoriatic by AbbVie — 4 open to participants now, 6 under way, 3 of them phase 3. Arthritis, Psoriatic · AbbVie.

Enrollment
3rd of 11
642 · median 246
Started
2017
with 2 others
Phase 3
5 of 34
1 open now
Registered
21st of 34
by date

Among the 34 studies in Arthritis, Psoriatic by AbbVie, this one is the 3rd largest by enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2017, is one of 5 in phase 3, and was the 21st registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

4 of the 34 studies in Arthritis, Psoriatic by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Arthritis, Psoriatic by AbbVie, or all of them as a file.
02

Study summary

This is a Phase 3 multicenter study that included two periods. Period 1 was designed to compare the safety, tolerability, and efficacy of upadacitinib 15 mg once daily (QD) and 30 mg QD versus placebo in participants with moderately to severely active Psoriatic Arthritis (PsA) who had an inadequate response to Biological Disease Modifying Anti-Rheumatic Drug (bDMARDs). Period 2 evaluated the safety, tolerability and efficacy of upadacitinib 15 mg QD and 30 mg QD in subjects with PsA who completed Period 1.

Read the detailed description

The study included a 35-day screening period; a 56-week blinded period which included 24 weeks of randomized, double-blind, parallel-group, placebo-controlled treatment followed by an additional 32 weeks of treatment blinded to the dose of upadacitinib (Period 1); a long-term extension period of up to a total treatment duration of up to approximately 3 years (Period 2); and a 30-day follow-up call or visit.

All participants in Period 1 who were randomized to receive Placebo up to 24 weeks were pooled for the assessment of all outcome measures. All participants receiving upadacitinib 30 mg QD during Period 2 were switched to upadacitinib 15 mg QD following a protocol amendment and were pooled for AE reporting.

03

Conditions studied

  • Psoriatic Arthritis

Keywords

  • Arthritis
  • Psoriasis
  • Anti-Rheumatic
  • Anti-inflammatory
  • Joint disease
  • Musculoskeletal disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of PsA with symptom onset at least 6 months prior to the Screening Visit and fulfillment of the Classification Criteria for PsA (CASPAR) criteria
  • Participant has active disease at Baseline defined as >= 3 tender joints (based on 68 joint counts) and >= 3 swollen joints (based on 66 joint counts) at Screening and Baseline Visits
  • Diagnosis of active plaque psoriasis or documented history of plaque psoriasis
  • Participant has had an inadequate response (lack of efficacy after a minimum 12 week duration of therapy) or intolerance to treatment with at least 1 bDMARD.

Exclusion criteria

Exclusion Criteria:

  • Prior exposure to any Janus Kinase (JAK) inhibitor (including but not limited to ruxolitinib, tofacitinib, baricitinib, and filgotinib)
  • Current treatment with > 2 non-biologic DMARDs or use of DMARDs other than Methotrexate (MTX), Sulfasalazine (SSZ), Leflunomide (LEF), apremilast, Hydroxychloroquine (HCQ), bucillamine or iguratimod or use of MTX in combination with LEF at Baseline.
  • History of fibromyalgia, any arthritis with onset prior to age 17 years, or current diagnosis of inflammatory joint disease other than PsA (including, but not limited to rheumatoid arthritis, gout, overlap connective tissue diseases, scleroderma, polymyositis, dermatomyositis, systemic lupus erythematosus). Prior history of reactive arthritis or axial spondyloarthritis including ankylosing spondylitis and non-radiographic axial spondyloarthritis is permitted if documentation of change in diagnosis to PsA or additional diagnosis of PsA is made. Prior history of fibromyalgia is permitted if documentation of change in diagnosis to PsA or documentation that the diagnosis of fibromyalgia was made incorrectly.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
642 participants (actual)

Study arms

  • Experimental
    Upadacitinib 15 mg

    Administered once daily.

    Drug: Upadacitinib

  • Placebo comparator
    Placebo / Upadacitinib 30 mg

    Administered once daily.

    Drug: Placebo · Drug: Upadacitinib

  • Experimental
    Upadacitinib 30 mg

    Administered once daily.

    Drug: Upadacitinib

  • Placebo comparator
    Placebo / Upadacitinib 15 mg

    Administered once daily.

    Drug: Placebo · Drug: Upadacitinib

Interventions

  • DrugPlacebo

    Oral tablet

  • Oral tablet

    Also known as: ABT-494

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12

    Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12

    The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from Baseline in the overall score indicates improvement.

    Time frame: Baseline and Week 12

  2. Percentage of Participants Achieving a Static Investigator Global Assessment (sIGA) of Psoriasis of 0 or 1 and at Least a 2-point Improvement From Baseline (sIGA 0/1) at Week 16

    The sIGA is a 5 point scale ranging from 0 to 4, based on the investigator's assessment of the average elevation, erythema, and scaling of all psoriatic lesions at the current visit. A lower score indicates less severe psoriasis (0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe).

    Time frame: Baseline and Week 16

  3. Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Response at Week 16

    PASI is a composite score based on the percentage of the body surface area (BSA) affected by psoriasis and the intensity of erythema (reddening), induration (thickening or hardening of the skin), and desquamation (peeling of the skin) of lesions assessed at 4 anatomic sites (head, upper extremities, trunk, and lower extremities). At each location, the percentage of BSA involvement is assigned a score from 0 (no involvement) to 6 (90% to 100% involvement), and erythema, induration, and desquamation are scored on a scale from 0 (no symptoms) to 4 (very marked). The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from Baseline in PASI score.

    Time frame: Baseline and Week 16

  4. Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12

    The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The physical component score is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The PCS was calculated using norm-based scoring so that 50 is the average score and the standard deviation equals 10. Higher scores are associated with better functioning/quality of life; a positive change from Baseline score indicates an improvement.

    Time frame: Baseline and Week 12

  5. Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 12

    The FACIT-Fatigue questionnaire is a self-administered patient questionnaire that consists of 13 questions designed to measure the degree of fatigue experienced by participants in the previous 7 days, including physical fatigue (e.g., I feel tired), functional fatigue (e.g., trouble finishing things), emotional fatigue (e.g., frustration), and social consequences of fatigue (e.g., limits social activity). Participants respond to the questions on a scale from 0 'not at all' to 4 'very much'. The FACIT Fatigue score is computed by summing the item scores, after reversing those items that are worded in the negative direction. The FACIT-Fatigue subscale score ranges from 0 to 52, where higher scores represent less fatigue. A positive change from Baseline indicates improvement.

    Time frame: Baseline and Week 12

  6. Percentage of Participants Achieving Minimal Disease Activity (MDA) at Week 24

    A participant was classified as achieving MDA if 5 of the following 7 criteria were met: * Tender joint count (out of 68 joints) ≤ 1 * Swollen joint count (out of 66 joints) ≤ 1 * PASI score ≤ 1 (score ranges from 0 - 72) or percent BSA involved with psoriasis ≤ 3% * Patient's assessment of pain ≤ 1.5 (NRS from 0 to 10) * Patient's Global Assessment of disease activity ≤ 2 (NRS from 0 to 10) * HAQ-DI score ≤ 0.5 (index score ranges from 0 to 3) * Leeds Enthesitis Index ≤ 1 (assesses the presence or absence of enthesitis at 3 bilateral sites, with an overall score range from 0 to 6)

    Time frame: Week 24

  7. Change From Baseline in Self-Assessment of Psoriasis Symptoms (SAPS) Score at Week 16

    The SAPS is an 11-item self-assessment of psoriasis symptoms that includes questions on: pain, itching, redness, scaling, flaking, bleeding, burning, stinging, tenderness, pain due to skin cracking, and joint pain. Each item is scored from 0 to 10, with 0 being least severe and 10 being most severe. The total score is generated by summing the 11 items and ranges from 0 to 110 (worst). A negative change from Baseline in the total score indicates improvement.

    Time frame: Baseline and Week 16

  8. Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12

    Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR50 response criteria: 1. ≥ 50% improvement in 68-tender joint count; 2. ≥ 50% improvement in 66-swollen joint count; and 3. ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

    Time frame: Baseline and Week 12

  9. Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12

    Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR70 response criteria: 1. ≥ 70% improvement in 68-tender joint count; 2. ≥ 70% improvement in 66-swollen joint count; and 3. ≥ 70% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

    Time frame: Baseline and Week 12

  10. Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 2

    Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

    Time frame: Baseline and Week 2

07

Results

Posted Jan 25, 2022

Participant flow

This study was conducted at 123 sites in 16 countries (Belgium, Brazil, Canada, Chile, Czech Republic, France, Greece, Hungary, Italy, Japan, Netherlands, New Zealand, Portugal, Spain, United Kingdom, United States \[including Puerto Rico\]). Adults with active psoriatic arthritis (PsA) and a history of inadequate response or intolerance to at least one biologic disease modifying anti-rheumatic drug (bDMARD) were enrolled.

Period 1
Participant flow — Period 1
MilestonePlacebo / Upadacitinib 15 mgPlacebo / Upadacitinib 30 mgUpadacitinib 15 mgUpadacitinib 30 mg
Started106106211219
Received study drug106106211218
Completed week 248192192195
Completed6977167166
Not completed37294453
Withdrew: Adverse event771214
Withdrew: Withdrawal by subject1891017
Withdrew: Lost to follow-up4468
Withdrew: Lack of efficacy67126
Withdrew: Other2247
Withdrew: One participant did not qualify per inclusion/exclusion criteria and discontinued prior to treatment0001
Period 2
Participant flow — Period 2
MilestonePlacebo / Upadacitinib 15 mgPlacebo / Upadacitinib 30 mgUpadacitinib 15 mgUpadacitinib 30 mg
Started6977167165
Switched to 15mg qd upa dosing in period 2028059
Completed5555131126
Not completed14223639
Withdrew: Adverse event471010
Withdrew: Withdrawal by subject371316
Withdrew: Lost to follow-up2235
Withdrew: Lack of efficacy2474
Withdrew: Covid-19 infection0010
Withdrew: Other3224

Outcome measures

PrimaryPercentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12

Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12
percentage of participantsPlaceboUpadacitinib 15 mgUpadacitinib 30 mg
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 1224.1 (18.3 to 29.8)56.9 (50.2 to 63.6)63.8 (57.4 to 70.1)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Response rate difference: 32.8 · 95% CI 24.0 to 41.6Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Response rate difference: 39.7 · 95% CI 31.1 to 48.3Response Rate Difference = Upadacitinib - Placebo
SecondaryChange From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12

The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from Baseline in the overall score indicates improvement.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12
score on a scalePlaceboUpadacitinib 15 mgUpadacitinib 30 mg
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12-0.10 (-0.16 to -0.03)-0.30 (-0.37 to -0.24)-0.41 (-0.47 to -0.35)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Mixed Effect Model Repeated Measurement · p = <0.0001 · Least squares (ls) mean difference: -0.21 · 95% CI -0.30 to -0.12Treatment Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · Mixed Effect Model Repeated Measurement · p = <0.0001 · Ls mean difference: -0.31 · 95% CI -0.40 to -0.22Treatment Difference = Upadacitinib - Placebo
SecondaryPercentage of Participants Achieving a Static Investigator Global Assessment (sIGA) of Psoriasis of 0 or 1 and at Least a 2-point Improvement From Baseline (sIGA 0/1) at Week 16

The sIGA is a 5 point scale ranging from 0 to 4, based on the investigator's assessment of the average elevation, erythema, and scaling of all psoriatic lesions at the current visit. A lower score indicates less severe psoriasis (0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe).

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Static Investigator Global Assessment (sIGA) of Psoriasis of 0 or 1 and at Least a 2-point Improvement From Baseline (sIGA 0/1) at Week 16
percentage of participantsPlaceboUpadacitinib 15 mgUpadacitinib 30 mg
Percentage of Participants Achieving a Static Investigator Global Assessment (sIGA) of Psoriasis of 0 or 1 and at Least a 2-point Improvement From Baseline (sIGA 0/1) at Week 169.2 (4.8 to 13.6)36.8 (29.6 to 44.1)40.2 (32.7 to 47.7)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Response rate difference: 27.6 · 95% CI 19.2 to 36.1Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Response rate difference: 31.0 · 95% CI 22.3 to 39.8Response Rate Difference = Upadacitinib - Placebo
SecondaryPercentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Response at Week 16

PASI is a composite score based on the percentage of the body surface area (BSA) affected by psoriasis and the intensity of erythema (reddening), induration (thickening or hardening of the skin), and desquamation (peeling of the skin) of lesions assessed at 4 anatomic sites (head, upper extremities, trunk, and lower extremities). At each location, the percentage of BSA involvement is assigned a score from 0 (no involvement) to 6 (90% to 100% involvement), and erythema, induration, and desquamation are scored on a scale from 0 (no symptoms) to 4 (very marked). The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from Baseline in PASI score.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Response at Week 16
percentage of participantsPlaceboUpadacitinib 15 mgUpadacitinib 30 mg
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Response at Week 1616.0 (9.7 to 22.3)52.3 (43.7 to 60.9)56.5 (48.0 to 65.0)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Response rate difference: 36.3 · 95% CI 25.6 to 46.9Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Response rate difference: 40.5 · 95% CI 29.9 to 51.0Response Rate Difference = Upadacitinib - Placebo
SecondaryChange From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12

The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The physical component score is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The PCS was calculated using norm-based scoring so that 50 is the average score and the standard deviation equals 10. Higher scores are associated with better functioning/quality of life; a positive change from Baseline score indicates an improvement.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12
score on a scalePlaceboUpadacitinib 15 mgUpadacitinib 30 mg
Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 121.62 (0.58 to 2.67)5.15 (4.14 to 6.15)7.06 (6.07 to 8.06)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Mixed Effect Model Repeated Measurement · p = <0.0001 · Ls mean difference: 3.52 · 95% CI 2.07 to 4.98Treatment Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · Mixed Effect Model Repeated Measurement · p = <0.0001 · Ls mean difference: 5.44 · 95% CI 3.99 to 6.88Treatment Difference = Upadacitinib - Placebo
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 12

The FACIT-Fatigue questionnaire is a self-administered patient questionnaire that consists of 13 questions designed to measure the degree of fatigue experienced by participants in the previous 7 days, including physical fatigue (e.g., I feel tired), functional fatigue (e.g., trouble finishing things), emotional fatigue (e.g., frustration), and social consequences of fatigue (e.g., limits social activity). Participants respond to the questions on a scale from 0 'not at all' to 4 'very much'. The FACIT Fatigue score is computed by summing the item scores, after reversing those items that are worded in the negative direction. The FACIT-Fatigue subscale score ranges from 0 to 52, where higher scores represent less fatigue. A positive change from Baseline indicates improvement.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 12
score on a scalePlaceboUpadacitinib 15 mgUpadacitinib 30 mg
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 121.3 (0.1 to 2.5)5.0 (3.8 to 6.1)6.1 (4.9 to 7.2)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Mixed Effect Model Repeated Measurement · p = <0.0001 · Ls mean difference: 3.7 · 95% CI 2.0 to 5.4Treatment Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · Mixed Effect Model Repeated Measurement · p = <0.0001 · Ls mean difference: 4.8 · 95% CI 3.1 to 6.4Treatment Difference = Upadacitinib - Placebo
SecondaryPercentage of Participants Achieving Minimal Disease Activity (MDA) at Week 24

A participant was classified as achieving MDA if 5 of the following 7 criteria were met: * Tender joint count (out of 68 joints) ≤ 1 * Swollen joint count (out of 66 joints) ≤ 1 * PASI score ≤ 1 (score ranges from 0 - 72) or percent BSA involved with psoriasis ≤ 3% * Patient's assessment of pain ≤ 1.5 (NRS from 0 to 10) * Patient's Global Assessment of disease activity ≤ 2 (NRS from 0 to 10) * HAQ-DI score ≤ 0.5 (index score ranges from 0 to 3) * Leeds Enthesitis Index ≤ 1 (assesses the presence or absence of enthesitis at 3 bilateral sites, with an overall score range from 0 to 6)

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Minimal Disease Activity (MDA) at Week 24
percentage of participantsPlaceboUpadacitinib 15 mgUpadacitinib 30 mg
Percentage of Participants Achieving Minimal Disease Activity (MDA) at Week 242.8 (0.6 to 5.1)25.1 (19.3 to 31.0)28.9 (22.9 to 34.9)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Response rate difference: 22.3 · 95% CI 16.0 to 28.6Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Response rate difference: 26.1 · 95% CI 19.7 to 32.5Response Rate Difference = Upadacitinib - Placebo
SecondaryChange From Baseline in Self-Assessment of Psoriasis Symptoms (SAPS) Score at Week 16

The SAPS is an 11-item self-assessment of psoriasis symptoms that includes questions on: pain, itching, redness, scaling, flaking, bleeding, burning, stinging, tenderness, pain due to skin cracking, and joint pain. Each item is scored from 0 to 10, with 0 being least severe and 10 being most severe. The total score is generated by summing the 11 items and ranges from 0 to 110 (worst). A negative change from Baseline in the total score indicates improvement.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in Self-Assessment of Psoriasis Symptoms (SAPS) Score at Week 16
score on a scalePlaceboUpadacitinib 15 mgUpadacitinib 30 mg
Change From Baseline in Self-Assessment of Psoriasis Symptoms (SAPS) Score at Week 16-1.5 (-4.7 to 1.8)-24.4 (-27.5 to -21.2)-29.7 (-32.8 to -26.6)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Mixed Effect Model Repeated Measurement · p = <0.0001 · Ls mean difference: -22.9 · 95% CI -27.4 to -18.4Treatment Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · Mixed Effect Model Repeated Measurement · p = <0.0001 · Ls mean difference: -28.2 · 95% CI -32.7 to -23.8Treatment Difference = Upadacitinib - Placebo
SecondaryPercentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12

Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR50 response criteria: 1. ≥ 50% improvement in 68-tender joint count; 2. ≥ 50% improvement in 66-swollen joint count; and 3. ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12
percentage of participantsPlaceboUpadacitinib 15 mgUpadacitinib 30 mg
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 124.7 (1.9 to 7.6)31.8 (25.5 to 38.0)37.6 (31.2 to 44.0)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Response rate difference: 27.0 · 95% CI 20.1 to 33.9Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Response rate difference: 32.9 · 95% CI 25.9 to 39.9Response Rate Difference = Upadacitinib - Placebo
SecondaryPercentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12

Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR70 response criteria: 1. ≥ 70% improvement in 68-tender joint count; 2. ≥ 70% improvement in 66-swollen joint count; and 3. ≥ 70% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12
percentage of participantsPlaceboUpadacitinib 15 mgUpadacitinib 30 mg
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 120.5 (0.0 to 1.4)8.5 (4.8 to 12.3)16.5 (11.6 to 21.4)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Response rate difference: 8.1 · 95% CI 4.2 to 11.9Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Response rate difference: 16.0 · 95% CI 11.0 to 21.1Response Rate Difference = Upadacitinib - Placebo
SecondaryPercentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 2

Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

Time frame:
Baseline and Week 2
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 2
percentage of participantsPlaceboUpadacitinib 15 mgUpadacitinib 30 mg
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 210.8 (6.7 to 15.0)32.7 (26.4 to 39.0)33.5 (27.2 to 39.8)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Response rate difference: 21.9 · 95% CI 14.3 to 29.4Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Response rate difference: 22.6 · 95% CI 15.1 to 30.2Response Rate Difference = Upadacitinib - Placebo

Adverse events

Collected over All-cause mortality and adverse event tables include events reported from enrollment to the end of the study. For Period 1, the median time participants were followed was: 414 days (15mg Upa); 413 days (30mg Upa); 190 days (Pooled Placebo ICF to week 24); 415 days (Pbo 15mg Upa); and 415 days (Pbo 30mg Upa). For Period 2, the median time participants were followed was: 712 days (15mg Upa); 701 days (30mg Upa); 703 days (Pbo 15mg Upa); 672 days (Pbo 30mg Upa); and 223 days (Switched to 15mg Upa).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Period 1: Upadacitinib 15 mg (ICF to Week 56)0/211 (0%)22/211 (10.4%)111/211 (52.6%)
Period 1: Upadacitinib 30 mg (ICF to Week 56)0/219 (0%)25/219 (11.4%)139/219 (63.5%)
Period 1: Pooled Placebo (ICF to Week 24)1/212 (0.5%)5/212 (2.4%)87/212 (41%)
Period 1: Placebo / Upadacitinib 15 mg (Week 24 to Week 56)0/79 (0%)3/79 (3.8%)32/79 (40.5%)
Period 1: Placebo / Upadacitinib 30 mg (Week 24 to Week 56)0/90 (0%)6/90 (6.7%)34/90 (37.8%)
Period 2: Upadacitinib 15 mg (Week 56 to EOS)5/167 (3%)24/167 (14.4%)111/167 (66.5%)
Period 2: Upadacitinib 30 mg (Week 56 to EOS)0/165 (0%)19/165 (11.5%)99/165 (60%)
Period 2: Placebo / Upadacitinib 15 mg (Week 56 to Week EOS)0/69 (0%)7/69 (10.1%)42/69 (60.9%)
Period 2: Placebo / Upadacitinib 30 mg (Week 56 to EOS)2/77 (2.6%)12/77 (15.6%)49/77 (63.6%)
Period 2: Pooled Upadacitinib Groups Who Switched From 30 mg to 15 mg in Period 20/87 (0%)5/87 (5.7%)34/87 (39.1%)
Most frequent serious events
Showing 10 of 137
Most frequent serious events
EventPeriod 1: Upadacitinib 15 mg (ICF to Week 56)Period 1: Upadacitinib 30 mg (ICF to Week 56)Period 1: Pooled Placebo (ICF to Week 24)Period 1: Placebo / Upadacitinib 15 mg (Week 24 to Week 56)Period 1: Placebo / Upadacitinib 30 mg (Week 24 to Week 56)Period 2: Upadacitinib 15 mg (Week 56 to EOS)Period 2: Upadacitinib 30 mg (Week 56 to EOS)Period 2: Placebo / Upadacitinib 15 mg (Week 56 to Week EOS)Period 2: Placebo / Upadacitinib 30 mg (Week 56 to EOS)Period 2: Pooled Upadacitinib Groups Who Switched From 30 mg to 15 mg in Period 2
PNEUMONIAInfections and infestations3/2113/2190/2121/790/900/1672/1650/691/772/87
COVID-19Infections and infestations0/2110/2190/2120/790/903/1670/1651/690/770/87
GASTRITISGastrointestinal disorders0/2110/2190/2120/790/900/1670/1651/690/770/87
CHOLELITHIASISHepatobiliary disorders0/2110/2190/2120/790/901/1670/1651/690/771/87
ABSCESSInfections and infestations0/2110/2190/2120/790/900/1670/1651/690/770/87
LIVER ABSCESSInfections and infestations0/2110/2190/2120/790/900/1670/1651/690/770/87
POST PROCEDURAL BILE LEAKInjury, poisoning and procedural complications0/2110/2190/2120/790/900/1670/1651/690/770/87
DIABETIC KETOACIDOSISMetabolism and nutrition disorders0/2110/2190/2120/790/900/1670/1651/690/770/87
BACK PAINMusculoskeletal and connective tissue disorders0/2110/2190/2120/790/900/1670/1651/690/770/87
DIZZINESSNervous system disorders1/2110/2190/2120/790/900/1670/1651/690/770/87
Most frequent other events
Showing 10 of 18
Most frequent other events
EventPeriod 1: Upadacitinib 15 mg (ICF to Week 56)Period 1: Upadacitinib 30 mg (ICF to Week 56)Period 1: Pooled Placebo (ICF to Week 24)Period 1: Placebo / Upadacitinib 15 mg (Week 24 to Week 56)Period 1: Placebo / Upadacitinib 30 mg (Week 24 to Week 56)Period 2: Upadacitinib 15 mg (Week 56 to EOS)Period 2: Upadacitinib 30 mg (Week 56 to EOS)Period 2: Placebo / Upadacitinib 15 mg (Week 56 to Week EOS)Period 2: Placebo / Upadacitinib 30 mg (Week 56 to EOS)Period 2: Pooled Upadacitinib Groups Who Switched From 30 mg to 15 mg in Period 2
COVID-19Infections and infestations0/2110/2190/2120/790/9021/16712/1657/697/7714/87
NASOPHARYNGITISInfections and infestations24/21129/21917/2125/796/9014/16712/1657/696/775/87
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations22/21129/21910/2126/792/9015/1679/1655/696/773/87
PSORIATIC ARTHROPATHYMusculoskeletal and connective tissue disorders13/2117/21911/2122/793/9012/16716/1659/698/778/87
URINARY TRACT INFECTIONInfections and infestations19/21116/21912/2124/794/9017/16714/1658/699/773/87
HYPERTENSIONVascular disorders8/21110/21910/2124/793/9019/16711/1655/697/771/87
BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations9/21122/2194/2122/794/9013/1679/1655/696/772/87
BRONCHITISInfections and infestations17/21115/2195/2125/794/9015/1678/1656/694/772/87
HERPES ZOSTERInfections and infestations8/21113/2192/2122/795/9010/16713/1653/695/771/87
SINUSITISInfections and infestations8/2119/2199/2123/792/907/1677/1652/696/770/87

Baseline characteristics

The Full Analysis Set (FAS) included all randomized participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)PlaceboUpadacitinib 15 mgUpadacitinib 30 mgTotal
Mean54.1 ± 11.5353.0 ± 12.0253.0 ± 11.9453.4 ± 11.83
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboUpadacitinib 15 mgUpadacitinib 30 mgTotal
Female120113115348
Male9298103293
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboUpadacitinib 15 mgUpadacitinib 30 mgTotal
Hispanic or Latino533650139
Not Hispanic or Latino159175168502
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboUpadacitinib 15 mgUpadacitinib 30 mgTotal
White186183196565
Black or African American75517
American Indian/Alaska Native0303
Native Hawaiian or other Pacific Islander1113
Asian17191652
Multiple1001
Extent of Psoriasis
Extent of Psoriasis(Participants)PlaceboUpadacitinib 15 mgUpadacitinib 30 mgTotal
< 3% BSA818187249
≥ 3% BSA131130131392
Number of Prior Failed Biologic DMARDs
Number of Prior Failed Biologic DMARDs(Participants)PlaceboUpadacitinib 15 mgUpadacitinib 30 mgTotal
0 bDMARDS18161751
1 bDMARD135126130391
2 bDMARDS353546116
≥ 3 bDMARDS24342583
Duration of Psoriatic Arthritis Symptoms
Duration of Psoriatic Arthritis Symptoms(years)PlaceboUpadacitinib 15 mgUpadacitinib 30 mgTotal
Mean14.6 ± 11.7012.2 ± 8.8113.3 ± 10.8413.4 ± 10.54
Duration of PsA Diagnosis
Duration of PsA Diagnosis(years)PlaceboUpadacitinib 15 mgUpadacitinib 30 mgTotal
Mean11.0 ± 10.339.6 ± 8.369.7 ± 8.7110.1 ± 9.18

7 further baseline measures are reported on the registry.

08

Study locations

165 sites
  • Alabama Medical Group, PC /ID# 159836
    Mobile, Alabama 36608-1787, United States
  • Arizona Arthritis & Rheumatology Research, PLLC /ID# 160047
    Mesa, Arizona 85210-6871, United States
  • Sun Valley Arthritis Center Ltd. /ID# 161203
    Peoria, Arizona 85381, United States
  • Duplicate_AZ Arthritis and Rheumotology Research, PLLC /ID# 160006
    Phoenix, Arizona 85032-9306, United States
  • Osteoporosis Medical Center /ID# 161411
    Beverly Hills, California 90211, United States
  • Covina Arthritis Clinic /ID# 159919
    Covina, California 91722, United States
  • Triwest Research Associates /ID# 159915
    El Cajon, California 92020, United States
  • Duplicate_Providence Medical Foundation /ID# 160005
    Fullerton, California 92835, United States
  • C.V. Mehta MD, Med Corporation /ID# 161192
    Hemet, California 92543, United States
  • Care Access Research, Huntington Beach /ID# 160049
    Huntington Beach, California 92648, United States
  • Purushotham & Akther Kotha MD, Inc /ID# 159834
    La Mesa, California 91942, United States
  • Stanford University School of Med /ID# 161402
    Stanford, California 94305-2200, United States
  • Inland Rheum Clin Trials Inc. /ID# 159839
    Upland, California 91786, United States
  • Medvin Clinical Research /ID# 160045
    Whittier, California 90606, United States
  • Denver Arthritis Clinic /ID# 159899
    Denver, Colorado 80230, United States
  • Colorado Arthritis Associates /ID# 159856
    Lakewood, Colorado 80228, United States
  • Duplicate_Arthritis & Rheumatic Disease Specialties /ID# 161409
    Aventura, Florida 33180, United States
  • International Medical Research /ID# 160051
    Daytona Beach, Florida 32117, United States
  • Precision Research Organization /ID# 161293
    Miami Lakes, Florida 33016-1501, United States
  • Duplicate_Suncoast Clinical Research /ID# 161417
    New Port Richey, Florida 34652, United States
  • Millennium Research /ID# 159833
    Ormond Beach, Florida 32174, United States
  • Arthritis Center, Inc. /ID# 163463
    Palm Harbor, Florida 34684, United States
  • Gulf Region Clinical Res Inst /ID# 159860
    Pensacola, Florida 32514, United States
  • Sarasota Arthritis Center /ID# 159854
    Sarasota, Florida 34239, United States
  • BayCare Medical Group /ID# 161405
    St. Petersburg, Florida 33705, United States
  • West Broward Rheumatology Associates /ID# 161412
    Tamarac, Florida 33321, United States
  • Clinical Research of West Florida - Tampa /ID# 160069
    Tampa, Florida 33606-1246, United States
  • Clinical Research of West Florida, Inc /ID# 159840
    Tampa, Florida 33606-1246, United States
  • USF Health Morsani Center for /ID# 161291
    Tampa, Florida 33612, United States
  • BayCare Medical Group, Inc. /ID# 159912
    Tampa, Florida 33614-7101, United States
  • Florida Medical Clinic /ID# 160013
    Zephyrhills, Florida 33542, United States
  • Jefrey D. Lieberman, MD, P.C. /ID# 159842
    Decatur, Georgia 30033, United States
  • Atlanta Research Center for Rheumatology /ID# 161201
    Marietta, Georgia 20060, United States
  • Velocity Clinical Research - Boise /ID# 159922
    Meridian, Idaho 83642, United States
  • Great Lakes Clinical Trials /ID# 163438
    Chicago, Illinois 60640, United States
  • Deerbrook Medical Associates /ID# 159815
    Libertyville, Illinois 60048, United States
  • Duplicate_Clinic of Robert Hozman/Clinical Investigation Specialists /ID# 160068
    Skokie, Illinois 60076, United States
  • The Arthritis & Diabetes Clinic, Inc. /ID# 161294
    Monroe, Louisiana 71203, United States
  • Arthritis Treatment Center /ID# 160053
    Frederick, Maryland 21204, United States
  • The Center for Rheumatology and Bone Research /ID# 159900
    Wheaton, Maryland 20902, United States
  • Clinical Pharmacology Study Group /ID# 158712
    Worcester, Massachusetts 01605, United States
  • Clinvest Research LLC /ID# 161208
    Springfield, Missouri 65807, United States
  • Westroads Clinical Research /ID# 160004
    Omaha, Nebraska 68114, United States
  • Atlantic Coast Research /ID# 159810
    Toms River, New Jersey 08755, United States
  • Duplicate_Arthritis and Osteo Assoc /ID# 160015
    Las Cruces, New Mexico 88011, United States
  • Center for Rheumatology LLP /ID# 167046
    Albany, New York 12203-3710, United States
  • St. Lawrence Health System /ID# 159857
    Potsdam, New York 13676, United States
  • DJL Clinical Research, PLLC /ID# 161414
    Charlotte, North Carolina 28211, United States
  • Physicians East, PA /ID# 159898
    Greenville, North Carolina 27834, United States
  • Shanahan Rheuma & Immuno /ID# 160012
    Raleigh, North Carolina 27617, United States
  • PMG Research of Wilmington LLC /ID# 161403
    Wilmington, North Carolina 28401, United States
  • Trinity Health Med Arts Clinic /ID# 159811
    Minot, North Dakota 58701, United States
  • STAT Research, Inc. /ID# 161416
    Vandalia, Ohio 45377-9464, United States
  • Health Research of Oklahoma /ID# 159913
    Oklahoma City, Oklahoma 73103-2400, United States
  • Altoona Ctr Clinical Res /ID# 159861
    Duncansville, Pennsylvania 16635, United States
  • University of Pittsburgh MC /ID# 161193
    Pittsburgh, Pennsylvania 15260, United States
  • Articularis Healthcare Group, Inc d/b/a Low Country Rheumatology /ID# 163462
    Summerville, South Carolina 29486-7887, United States
  • Rheumatology Consultants, PLLC /ID# 161408
    Knoxville, Tennessee 37909, United States
  • Dr. Ramesh Gupta /ID# 160067
    Memphis, Tennessee 38119, United States
  • Tekton Research, Inc. /ID# 160008
    Austin, Texas 78745, United States
  • Diagnostic Group /ID# 161406
    Beaumont, Texas 77701, United States
  • Arthritis and Osteoporosis Clinic Of Brazos Valley /ID# 163439
    College Station, Texas 77845, United States
  • Adriana Pop-Moody MD Clinic PA /ID# 160009
    Corpus Christi, Texas 78404, United States
  • Metroplex Clinical Research /ID# 159818
    Dallas, Texas 75231, United States
  • Rheumatic Disease Clin Res Ctr /ID# 161252
    Houston, Texas 77004, United States
  • Accurate Clinical Research /ID# 160052
    Houston, Texas 77089, United States
  • P&I Clinical Research /ID# 159837
    Lufkin, Texas 75904-3132, United States
  • SW Rheumatology Res. LLC /ID# 160014
    Mesquite, Texas 75150, United States
  • DM Clinical Research - Tomball /ID# 161753
    Tomball, Texas 77375, United States
  • Arthritis & Osteoporosis Clinic /ID# 161400
    Waco, Texas 76710, United States
  • Arthritis Clinic of N. VA, P.C /ID# 159858
    Arlington, Virginia 22205, United States
  • Duplicate_Swedish Medical Center /ID# 159918
    Seattle, Washington 98104, United States
  • Emeritus Research Sydney /ID# 166751
    Botany, New South Wales 2019, Australia
  • The Queen Elizabeth Hospital /ID# 200840
    Woodville South, South Australia 5011, Australia
  • Box Hill Hospital /ID# 166752
    Box Hill, Victoria 3128, Australia
  • Heidelberg Repatriation Hospital /ID# 167441
    Heidelberg West, Victoria 3081, Australia
  • ReumaClinic /ID# 164214
    Genk, Limburg 3600, Belgium
  • UZ Gent /ID# 164210
    Ghent, Oost-Vlaanderen 9000, Belgium
  • CIP - Centro Internacional de Pesquisa /ID# 161808
    Goiânia, Goiás 74110-120, Brazil
  • Faculdade de Medicina do ABC /ID# 163489
    Santo André, La Spezia 09060-870, Brazil
  • Hospital de Clínicas da Universidade Federal de Uberlândia /ID# 161794
    Uberlândia, Minas Gerais 38400-902, Brazil
  • Hospital de Clinicas de Porto Alegre /ID# 161795
    Porto Alegre, Rio Grande do Sul 90035-903, Brazil
  • LMK Sevicos Medicos S/S /ID# 161806
    Porto Alegre, Rio Grande do Sul 90480-000, Brazil
  • Duplicate_Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto - USP /ID# 163317
    Ribeirão Preto, São Paulo 14051-140, Brazil
  • Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao /ID# 161793
    São Paulo, 05403-000, Brazil
  • Percuro Clinical Research, Ltd /ID# 157835
    Victoria, British Columbia V8V 3M9, Canada
  • CIADS Research Co Ltd /ID# 157843
    Winnipeg, Manitoba R3N 0K6, Canada
  • The Waterside Clinic /ID# 157838
    Orillia, Ontario L3V 1T5, Canada
  • Groupe de Recherche en Maladies Osseuses Inc /ID# 157836
    Sainte-Foy, Quebec G1V 3M7, Canada
  • Centre de Recherche Musculo-Squelettique /ID# 163557
    Trois-Rivières, Quebec G8Z 1Y2, Canada
  • CTR Estudios Clinicos /ID# 206038
    Providencia, Aysén 7500571, Chile
  • Duplicate_Clinica Dermacross /ID# 169537
    Santiago, 7640881, Chile
  • Duplicate_Centro Internacional de Estudios Clinicos /ID# 169543
    Santiago, 8420383, Chile
  • Prosalud Ltda. /ID# 169542
    Santiago, ZC:7510047, Chile
  • Revmatologie Bruntal, s.r.o /ID# 159632
    Prostějov, 796 01, Czechia
  • Medical Plus, s.r.o. /ID# 159631
    Uherské Hradiště, 686 01, Czechia
  • Hopital Saint Joseph /ID# 163755
    Marseille, Bouches-du-Rhone 13008, France
  • CHU Toulouse /ID# 163743
    Toulouse, Occitanie 31300, France
  • Centre Hospitalier du Mans /ID# 163746
    Le Mans, Sarthe 72037, France
  • CHRU Tours - Hopital Trousseau /ID# 163772
    Chambray-lès-Tours, 37170, France

Showing the first 100 of 165 sites across 19 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Burmester GR, Deodhar A, Irvine AD, Panaccione R, Winthrop KL, Vleugels RA, Levy G, Suravaram S, Palac H, Wegrzyn L, Ford S, Meerwein S, Guttman-Yassky E. Safety Profile of Upadacitinib: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel Disease. Adv Ther. 2025 Oct;42(10):5215-5237. doi: 10.1007/s12325-025-03328-y. Epub 2025 Aug 28. PubMed 40875187 ↗
  • Burmester GR, Stigler J, Rubbert-Roth A, Tanaka Y, Azevedo VF, Coombs D, Lagunes I, Lippe R, Wung P, Gensler LS. Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials. Rheumatol Ther. 2024 Jun;11(3):737-753. doi: 10.1007/s40744-024-00671-4. Epub 2024 Apr 29. PubMed 38683479 ↗
  • Cantini F, Marchesoni A, Novelli L, Gualberti G, Marando F, McDearmon-Blondell EL, Gao T, McGonagle D, Salvarani C. Effects of upadacitinib on enthesitis in patients with psoriatic arthritis: a post hoc analysis of SELECT-PsA 1 and 2 trials. Rheumatology (Oxford). 2024 Nov 1;63(11):3146-3154. doi: 10.1093/rheumatology/keae057. PubMed 38331400 ↗
  • Rubbert-Roth A, Kakehasi AM, Takeuchi T, Schmalzing M, Palac H, Coombs D, Liu J, Anyanwu SI, Lippe R, Curtis JR. Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis. Rheumatol Ther. 2024 Feb;11(1):97-112. doi: 10.1007/s40744-023-00621-6. Epub 2023 Nov 20. PubMed 37982966 ↗
  • Charles-Schoeman C, Choy E, McInnes IB, Mysler E, Nash P, Yamaoka K, Lippe R, Khan N, Shmagel AK, Palac H, Suboticki J, Curtis JR. MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. RMD Open. 2023 Nov;9(4):e003392. doi: 10.1136/rmdopen-2023-003392. PubMed 37945286 ↗
  • Mease P, Setty A, Papp K, Van den Bosch F, Tsuji S, Keiserman M, Carter K, Li Y, McCaskill R, McDearmon-Blondell E, Wung P, Tillett W. Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 study. Clin Exp Rheumatol. 2023 Nov;41(11):2286-2297. doi: 10.55563/clinexprheumatol/8l7bbk. Epub 2023 Jul 5. PubMed 37404160 ↗
  • Burmester GR, Cohen SB, Winthrop KL, Nash P, Irvine AD, Deodhar A, Mysler E, Tanaka Y, Liu J, Lacerda AP, Palac H, Shaw T, Mease PJ, Guttman-Yassky E. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 2023 Feb;9(1):e002735. doi: 10.1136/rmdopen-2022-002735. PubMed 36754548 ↗
  • Mease P, Kavanaugh A, Gladman D, FitzGerald O, Soriano ER, Nash P, Feng D, Lertratanakul A, Douglas K, Lippe R, Gossec L. Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials. Rheumatol Ther. 2022 Aug;9(4):1181-1191. doi: 10.1007/s40744-022-00449-6. Epub 2022 May 23. PubMed 35606663 ↗
  • Burmester GR, Winthrop K, Blanco R, Nash P, Goupille P, Azevedo VF, Salvarani C, Rubbert-Roth A, Lesser E, Lippe R, Lertratanakul A, Mccaskill RM, Liu J, Ruderman EM. Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials. Rheumatol Ther. 2022 Apr;9(2):521-539. doi: 10.1007/s40744-021-00410-z. Epub 2021 Dec 30. PubMed 34970731 ↗
  • Nash P, Richette P, Gossec L, Marchesoni A, Ritchlin C, Kato K, McDearmon-Blondell EL, Lesser E, McCaskill R, Feng D, Anderson JK, Ruderman EM. Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis. Rheumatology (Oxford). 2022 Aug 3;61(8):3257-3268. doi: 10.1093/rheumatology/keab905. PubMed 34864911 ↗
  • Strand V, Van den Bosch F, Ranza R, Leung YY, Drescher E, Zueger P, Saffore CD, Lertratanakul A, Lippe R, Nash P. Patient-Reported Outcomes in Psoriatic Arthritis Patients with an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: SELECT-PsA 2. Rheumatol Ther. 2021 Dec;8(4):1827-1844. doi: 10.1007/s40744-021-00377-x. Epub 2021 Oct 18. PubMed 34661885 ↗
  • Muensterman E, Engelhardt B, Gopalakrishnan S, Anderson JK, Mohamed MF. Upadacitinib pharmacokinetics and exposure-response analyses of efficacy and safety in psoriatic arthritis patients - Analyses of phase III clinical trials. Clin Transl Sci. 2022 Jan;15(1):267-278. doi: 10.1111/cts.13146. Epub 2021 Oct 27. PubMed 34464029 ↗
  • Mease PJ, Lertratanakul A, Papp KA, van den Bosch FE, Tsuji S, Dokoupilova E, Keiserman MW, Bu X, Chen L, McCaskill RM, Zueger P, McDearmon-Blondell EL, Pangan AL, Tillett W. Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study. Rheumatol Ther. 2021 Jun;8(2):903-919. doi: 10.1007/s40744-021-00305-z. Epub 2021 Apr 28. PubMed 33913086 ↗
  • Mease PJ, Lertratanakul A, Anderson JK, Papp K, Van den Bosch F, Tsuji S, Dokoupilova E, Keiserman M, Wang X, Zhong S, McCaskill RM, Zueger P, Pangan AL, Tillett W. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis. 2021 Mar;80(3):312-320. doi: 10.1136/annrheumdis-2020-218870. Epub 2020 Dec 3. PubMed 33272960 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Jul 2019, 26 months.

Results were first posted in Jan 2022, 2 years 6 months after primary completion. A results delay was requested in Jul 2020.

Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 26 months is close to that.

Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2017
First posted
Apr 7, 2017
StartActual
May 1, 2017
Primary completionActual
Jul 23, 2019
CompletionActual
Sep 30, 2024
Results delay requested
Jul 14, 2020
Results first posted
Jan 25, 2022
Last update
Sep 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03104374
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Apr 7, 2017
Start date
May 1, 2017
Primary completion
Jul 23, 2019
Completion
Sep 30, 2024
Results posted
Jan 25, 2022
Last update
Sep 11, 2025

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Upadacitinib

Start the discussion